Stock of The Day: Milestone Pharmaceuticals, Inc.(NASDAQ:MIST) UP++166%

Company Profile

Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is its short-acting calcium channel blocker. It is developing Etripamil as a nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia (PSVT), as they occur. It is also focused on developing treatments for other indications, such as Atrial Fibrillation and Angina. Etripamil is in Phase-III development for PSVT.

(NASDAQ:MIST) 1 day chart 7/23/20


Sector: Health Technology

Industry: Pharmaceuticals:

Employees: 30

Milestone Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. The firm designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.

Milestone Pharma provides update on late stage etripamil study; secures $25M in equity

Milestone Pharmaceuticals Announces Regulatory Guidance and Updated Clinical Development Plan for Etripamil in PSVT

Milestone Pharmaceuticals News: Why MIST Stock Is Skyrocketing 114% Today

Milestone Pharmaceuticals, Inc.(NASDAQ:MIST) 1 year chart 7/23/20

Leave a Reply

Your email address will not be published. Required fields are marked *